Market Cap 856.67B
Revenue (ttm) 65.18B
Net Income (ttm) 20.64B
EPS (ttm) N/A
PE Ratio 37.90
Forward PE 26.41
Profit Margin 31.67%
Debt to Equity Ratio 1.54
Volume 4,818,700
Avg Vol 3,216,132
Day's Range N/A - N/A
Shares Out 944.82M
Stochastic %K 7%
Beta 0.40
Analysts Strong Sell
Price Target $1,235.07

Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
Capitulation_0
Capitulation_0 Mar. 21 at 10:41 PM
$LLY, $XBI lly M&A chief...somethings wrong with how they do M&A these days...."and those are the ones where I'm particularly surprised you put sort of a market premium offer on the table, and you're not even granted a conversation, so to speak, as you have a conversation, but it sort of doesn't go anywhere. That's pretty surprising, and that's that's happening more frequently than I would have expected."
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 21 at 6:29 PM
Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80% $GLENMARK.NSE $OZEM $LLY $NVO https://stocktwits.com/news/equity/markets/glenmark-debuts-budget-semaglutide-in-india/cZ3i3maRIih
0 · Reply
rayTrade81
rayTrade81 Mar. 21 at 5:07 PM
$LLY big pharma leader still acts like a safe trend and that matters in mixed tape
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 3:58 PM
0 · Reply
biolover
biolover Mar. 21 at 2:53 PM
$VKTX TZP half life 5 days. Vk2835 8.5 days. It can make a difference. Particularly with orals that can accumulate. Could be more difficult to make TZP oral. We don’t know if $LLY attempted. If orfoglipron shows liver toxicity ( my estimate 1/300 pts ) …again If. Lilly will find itself behind here. $GPCR could show ALT > x5-10 at 1-100-200 .. will see. I could be wrong here. AZN orfor like molecule had one case of liver toxicity in phase 1. Look at exposure. I think VK2735 could be slightly exaggerated on this modeling as phase 2 had more females. But if it beats by 1% at 12 wks. It can make a difference long term. This is what $NVO needs.
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 21 at 12:22 PM
$NVO $LLY GLP‑1 spotlight: India’s obesity market is about to get a new disruptor. Dr. Reddy’s is gearing up to launch generic semaglutide in the coming months, targeting both weight management and diabetes segments. 👉If this is helpful to you, tap @NasdaqKnight Key points: • Partnering with top Indian pharma players for branded distribution — this isn’t a small regional push. • Higher-dose versions planned, aiming to compete directly with premium branded options. Real-time context: GLP‑1 adoption is exploding globally, but India remains largely untapped. With generics entering the market, patient access and affordability will surge, while market share pressure ramps up on $NVO and $LLY’s branded sales. This is more than a pipeline move — it’s strategic positioning in the next wave of obesity therapeutics. Watch pricing, launch cadence, and uptake metrics over the next few months — early adoption trends could reshape the GLP‑1 competitive landscape in India.
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 5:46 AM
Transformative Or Overhyped? The Impact Of Weight-Loss Drugs On European Food Demand $LLY $NVO https://talkmarkets.com/article/transformative-or-overhyped-the-impact-of-weight-loss-drugs-on-european-food-demand-1774071550
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 5:41 AM
Transformative Or Overhyped? The Impact Of Weight-Loss Drugs On European Food Demand $LLY $NVO https://talkmarkets.com/article/transformative-or-overhyped-the-impact-of-weight-loss-drugs-on-european-food-demand-1774071550
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:50 AM
$LLY Eli Lilly (NYSE:LLY) is leading the global obesity and diabetes revolution with blockbuster GLP-1 drugs like Mounjaro. With massive prescription growth and a $1,300 price target, this healthcare giant could still have significant upside ahead. https://biotechhealthx.com/biotech-news/is-eli-lilly-and-company-lly-a-smart-long-term-investment/
0 · Reply
oldmanrizzer
oldmanrizzer Mar. 20 at 11:11 PM
$HIMS $NVO $LLY $VKTX GLP-1 stocks are cooked. Do we think they'll ever hit the heights at the start of the craze or even recover for that matter? Crazy how the weight loss industry generates billions upon billions of dollars yet the real money wants nothing to do with these stocks. I wish NVO could just get rid of the GLP1 business all together, layoff 50-60% more of the company and go back to focusing on their other products. The stock actually did better then. Soon there will about 100 companies producing GLP1 pills. I honestly don't like how this all transpired so quickly with so many analysts posting bearish sentiment that GLP1 is way overstated in demand.
4 · Reply
Latest News on LLY
Our Top 10 High Growth Dividend Stocks - March 2026

Mar 21, 2026, 8:15 AM EDT - 14 hours ago

Our Top 10 High Growth Dividend Stocks - March 2026

APH AU CCJ CIB COKE CVE FIX


Why Eli Lilly Remains My Top Obesity Bet

Mar 20, 2026, 1:38 PM EDT - 1 day ago

Why Eli Lilly Remains My Top Obesity Bet


Stock Of The Day: Is The Eli Lilly Selloff Over?

Mar 18, 2026, 1:30 PM EDT - 3 days ago

Stock Of The Day: Is The Eli Lilly Selloff Over?


Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations

Mar 17, 2026, 12:57 PM EDT - 4 days ago

Eli Lilly Analyst Flags Overhyped Obesity Drug Expectations


4 Stocks To Buy While Everyone Else Doubts AI

Mar 17, 2026, 12:25 PM EDT - 4 days ago

4 Stocks To Buy While Everyone Else Doubts AI

MU NFLX NVDA


Eli Lilly: The Weight-Loss Craze Isn't Over

Mar 12, 2026, 6:54 AM EDT - 9 days ago

Eli Lilly: The Weight-Loss Craze Isn't Over


Eli Lilly to invest $3 billion in China over next decade

Mar 11, 2026, 5:13 AM EDT - 10 days ago

Eli Lilly to invest $3 billion in China over next decade


Is Lilly Stock Still The Best Growth Story In Healthcare?

Mar 10, 2026, 1:20 PM EDT - 11 days ago

Is Lilly Stock Still The Best Growth Story In Healthcare?


What Are The Biggest Risks To Eli Lilly Stock?

Mar 5, 2026, 10:25 AM EST - 16 days ago

What Are The Biggest Risks To Eli Lilly Stock?


Why Eli Lilly is Winning the Weight Loss War

Feb 27, 2026, 12:30 PM EST - 22 days ago

Why Eli Lilly is Winning the Weight Loss War


Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen

Feb 23, 2026, 12:06 PM EST - 26 days ago

Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen


Novo Nordisk's Loss Is Eli Lilly's Gain

Feb 23, 2026, 11:42 AM EST - 26 days ago

Novo Nordisk's Loss Is Eli Lilly's Gain

NVO


Capitulation_0
Capitulation_0 Mar. 21 at 10:41 PM
$LLY, $XBI lly M&A chief...somethings wrong with how they do M&A these days...."and those are the ones where I'm particularly surprised you put sort of a market premium offer on the table, and you're not even granted a conversation, so to speak, as you have a conversation, but it sort of doesn't go anywhere. That's pretty surprising, and that's that's happening more frequently than I would have expected."
0 · Reply
StocktwitsNews
StocktwitsNews Mar. 21 at 6:29 PM
Glenmark Debuts Budget Semaglutide In India, Undercutting Ozempic By Over 80% $GLENMARK.NSE $OZEM $LLY $NVO https://stocktwits.com/news/equity/markets/glenmark-debuts-budget-semaglutide-in-india/cZ3i3maRIih
0 · Reply
rayTrade81
rayTrade81 Mar. 21 at 5:07 PM
$LLY big pharma leader still acts like a safe trend and that matters in mixed tape
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Mar. 21 at 3:58 PM
0 · Reply
biolover
biolover Mar. 21 at 2:53 PM
$VKTX TZP half life 5 days. Vk2835 8.5 days. It can make a difference. Particularly with orals that can accumulate. Could be more difficult to make TZP oral. We don’t know if $LLY attempted. If orfoglipron shows liver toxicity ( my estimate 1/300 pts ) …again If. Lilly will find itself behind here. $GPCR could show ALT > x5-10 at 1-100-200 .. will see. I could be wrong here. AZN orfor like molecule had one case of liver toxicity in phase 1. Look at exposure. I think VK2735 could be slightly exaggerated on this modeling as phase 2 had more females. But if it beats by 1% at 12 wks. It can make a difference long term. This is what $NVO needs.
0 · Reply
NasdaqKnight
NasdaqKnight Mar. 21 at 12:22 PM
$NVO $LLY GLP‑1 spotlight: India’s obesity market is about to get a new disruptor. Dr. Reddy’s is gearing up to launch generic semaglutide in the coming months, targeting both weight management and diabetes segments. 👉If this is helpful to you, tap @NasdaqKnight Key points: • Partnering with top Indian pharma players for branded distribution — this isn’t a small regional push. • Higher-dose versions planned, aiming to compete directly with premium branded options. Real-time context: GLP‑1 adoption is exploding globally, but India remains largely untapped. With generics entering the market, patient access and affordability will surge, while market share pressure ramps up on $NVO and $LLY’s branded sales. This is more than a pipeline move — it’s strategic positioning in the next wave of obesity therapeutics. Watch pricing, launch cadence, and uptake metrics over the next few months — early adoption trends could reshape the GLP‑1 competitive landscape in India.
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 5:46 AM
Transformative Or Overhyped? The Impact Of Weight-Loss Drugs On European Food Demand $LLY $NVO https://talkmarkets.com/article/transformative-or-overhyped-the-impact-of-weight-loss-drugs-on-european-food-demand-1774071550
0 · Reply
TalkMarkets
TalkMarkets Mar. 21 at 5:41 AM
Transformative Or Overhyped? The Impact Of Weight-Loss Drugs On European Food Demand $LLY $NVO https://talkmarkets.com/article/transformative-or-overhyped-the-impact-of-weight-loss-drugs-on-european-food-demand-1774071550
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 21 at 4:50 AM
$LLY Eli Lilly (NYSE:LLY) is leading the global obesity and diabetes revolution with blockbuster GLP-1 drugs like Mounjaro. With massive prescription growth and a $1,300 price target, this healthcare giant could still have significant upside ahead. https://biotechhealthx.com/biotech-news/is-eli-lilly-and-company-lly-a-smart-long-term-investment/
0 · Reply
oldmanrizzer
oldmanrizzer Mar. 20 at 11:11 PM
$HIMS $NVO $LLY $VKTX GLP-1 stocks are cooked. Do we think they'll ever hit the heights at the start of the craze or even recover for that matter? Crazy how the weight loss industry generates billions upon billions of dollars yet the real money wants nothing to do with these stocks. I wish NVO could just get rid of the GLP1 business all together, layoff 50-60% more of the company and go back to focusing on their other products. The stock actually did better then. Soon there will about 100 companies producing GLP1 pills. I honestly don't like how this all transpired so quickly with so many analysts posting bearish sentiment that GLP1 is way overstated in demand.
4 · Reply
DragonAlgo
DragonAlgo Mar. 20 at 8:04 PM
🐉 $LLY PUT — DragonAlgo® Signal Contract: LLY PUT Expiry: 2026-03-20 | Strike: $920.00 | Type: PUT Option Plan (premium): Entry: $18.25 Stop: $13.14 TP1: $23.73 TP2: $31.02 TP3: $43.80 🔗 https://dragonalgo.com
0 · Reply
TradeTracs
TradeTracs Mar. 20 at 7:26 PM
MFN drug pricing is moving from executive order to legislation — and Big Pharma is now at the table. ⚠️ $JNJ holding $237.60, sitting between SMA50 ($233.58) and SMA20 ($243.07), RSI 45. Relative strength vs peers. $LLY at $917.50 — down 14.63% YTD, RSI 32, still below both key MAs. $NVO is the wreckage: -27.12% YTD, RSI 31.82, near 52-week low of $35.85. Codifying MFN = structural margin pressure. Watch $JNJ SMA20 as resistance. $LLY and $NVO look like falling knives until legislative clarity arrives. #Pharma #DrugPricing #Biotech
0 · Reply
TradeTracs
TradeTracs Mar. 20 at 7:25 PM
Futures were wslipping Friday as Hormuz headlines steal focus — here's what's on the radar 👀 $LLY at $917.50, RSI 32 and buried under all key MAs. Down 14.6% YTD and bleeding through Q2. $917 near the SMA 200 at $891 — that's your last real support. $NVS fading hard at $148.19, off 10.4% in a month, RSI 32.94. Oversold but no floor yet. $AMZN holding $208.76, below all SMAs, RSI 44 — not oversold, just weak. Watch $LLY SMA 200 for a bounce or break. #Stocks #Trading #StockMarket
0 · Reply
janthony23
janthony23 Mar. 20 at 7:23 PM
$LLY - Back up the truck! Time to load up
0 · Reply
moenychaser
moenychaser Mar. 20 at 6:46 PM
$LLY let it fall bulltards
0 · Reply
Quantumup
Quantumup Mar. 20 at 6:14 PM
Raymond James reiterated $RLAY Strong Buy; $19 $NVS $LLY $CELC $AZN Here's what Raymond James had to say in its note to investors: https://x.com/Quantumup1/status/2035057217804636248?s=20
0 · Reply
mananpat3l
mananpat3l Mar. 20 at 6:05 PM
0 · Reply
designedmemory
designedmemory Mar. 20 at 5:54 PM
$LLY HSBC is now blocked from buying this up for a discount. Right? Because that would be an SEC violation…? Right?
1 · Reply
Jimmyboy29
Jimmyboy29 Mar. 20 at 5:53 PM
$LLY time to pivot back to $NVO & $MRK if you have any meaningful market expeirience. $XLV
0 · Reply
chuckieclam
chuckieclam Mar. 20 at 5:39 PM
$LLY wheres that jeet from hong kong bank that downgraded the stock?
1 · Reply
Flabslab
Flabslab Mar. 20 at 4:12 PM
$LLY So it's going to sit here until Orforglipron approval. Got it.
1 · Reply
NasdaqKnight
NasdaqKnight Mar. 20 at 3:50 PM
🚨 LEVELS TO WATCH 🚨 👉If this is helpful to you, tap @NasdaqKnight $LLY $AAPL $QCOM are all testing KEY technical levels this morning. The tape is heavy. Are we getting a shakeout or a breakdown? Here is the data: $LLY Trading ~$918.76 (+0.14%) . Holding above the $910 support zone. RSI neutral. Watching for volume to pick up. Big Pharma holding the line. $AAPL $247.15 (-0.73%) . Resistance at $251, support at $247. Is the smart money accumulating here? PE ~30.8x . 3.63T market cap. $QCOM RSI just hit 35.12 (Oversold territory) Seaport downgraded this week, but BOD just authorized a MASSIVE $20B buyback . Institutions still hold 76.6% . Insiders selling? Yes. But that buyback is ABSURD. The Catch: Financially, $GENK is a high-risk/high-reward play. Market cap is tiny (~$8.99M). P/S ratio: 0.04 (deep value?) . Altman Z-Score: 0.66 (Distress zone)
0 · Reply